FMGE oriented Integrated details notes on BCC(ENT). Write everything clearly and properly from FMGE toppers point of view. Don't leave any important point which can be asked in FMGE as potential question.

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Now I have extensive material from authoritative ENT and dermatology textbooks. Let me compile the comprehensive FMGE-oriented notes on BCC in ENT:

FMGE Integrated Notes: Basal Cell Carcinoma (BCC) - ENT/Head & Neck Focus

Sources: KJ Lee's Essential Otolaryngology, Cummings Otolaryngology Head & Neck Surgery, Fitzpatrick's Dermatology, Andrews' Diseases of the Skin

1. OVERVIEW - HIGH YIELD FACTS

Feature	Detail
Most common cutaneous malignancy	Yes - in adults
Proportion of NMSC	70-75% of all NMSC
Incidence	2.8 million cases/year (USA)
Compared to SCC	Twice as common as cSCC
AJCC Staging	NO formal AJCC staging system for BCC
Metastatic potential	Very low (< 0.1%) but locally aggressive
Mortality	Very low; 2,500 deaths/year NMSC overall

FMGE Fact: BCC is the most common skin cancer overall and the most common cancer in humans. It does NOT have a formal AJCC staging system (unlike SCC, melanoma).

2. ETIOLOGY AND RISK FACTORS

Environmental

Ultraviolet radiation (UVR) - leading cause
Fitzpatrick skin type I: fair skin, red/blonde hair, marked freckling
Tanning booth use
Previous radiation exposure

Genetic

PTCH1 (Patched-1) mutation on chromosome 9q - encodes the sonic hedgehog receptor
- Underlying cause of Nevoid BCC Syndrome (Gorlin syndrome)
Xeroderma Pigmentosum (XP): autosomal recessive; inability to repair UV-damaged DNA; associated with multiple BCCs and SCCs
Fanconi anemia
Immunosuppression (solid organ transplants, HIV/AIDS, lymphoproliferative disorders)

FMGE Fact: PTCH1 on chromosome 9q = Gorlin syndrome. XP = autosomal recessive. Avoid radiation in patients with Gorlin syndrome and other genetic predispositions.

3. GORLIN SYNDROME (Nevoid BCC Syndrome)

Feature	Detail
Gene	PTCH1 (chromosome 9q) - Sonic Hedgehog pathway
Inheritance	Autosomal dominant
Skin	Multiple BCCs (appear before age 35)
Jaw	Odontogenic keratocysts (multiple, recurrent)
Skeletal	Bifid ribs, calcification of falx cerebri
Other	Macrocephaly, medulloblastoma (desmoplastic type)
Classic triad	Multiple BCCs + Jaw cysts + Bifid rib

FMGE Fact: Gorlin syndrome = PTCH1 mutation = "BCC + Jaw cysts + Bifid rib." Radiation is contraindicated in Gorlin syndrome (induces more BCCs).

4. CLINICAL SUBTYPES OF BCC

A. Nodular BCC (most common)

Pearly papule with telangiectatic borders - classic appearance
Rolled, translucent border
May ulcerate centrally = "rodent ulcer"
Histology: palisading nuclei, decreased cytoplasm
Treatment: local excision (0.5-cm margins) or Mohs

B. Superficial BCC

Slow-growing, nonaggressive
Scaly, erythematous plaques
Most commonly on trunk/shoulders
Treatment: 5-FU, cryotherapy, photodynamic therapy (PDT), curettage, or Mohs

C. Sclerosing / Morpheaform BCC (most aggressive)

Indurated, scar-like, ill-defined plaque
Small strands of tumor extend from central lesion = "skip lesions" (neurotropism)
High recurrence rates, large surgical defects
Requires Mohs surgery
HIGH RISK subtype

D. Basosquamous (Metatypical) BCC

Squamous differentiation and keratinization
Can be confused with SCC
Aggressive - higher metastatic potential than typical BCC
Treatment: Mohs or wide local excision
HIGH RISK subtype

E. Other High-Risk Subtypes

Mixed infiltrative
Micronodular

FMGE Trick: "Morpheaform = most aggressive BCC = looks like a scar = skip lesions = Mohs." Nodular = most common BCC = pearly + telangiectasias.

5. BCC IN ENT/HEAD AND NECK (SITE-SPECIFIC)

H-Zone (Highest Risk Areas for BCC Recurrence)

The H-zone encompasses:

Nose (most common site overall)
Eyelids/brows, periorbital skin
Temples
Lips (cutaneous)
Ears and periauricular/postauricular region
Chin, mandible

FMGE Fact: H-zone = High-risk zone for BCC. BCC on the nose/ear/eyelid = always HIGH RISK regardless of size.

BCC of the External Auditory Canal (EAC)

EAC: SCC is most common malignant tumor, followed by BCC, then adenoid cystic carcinoma
External auricle is commonly affected (sun exposure)
Scalp also at risk

BCC and Perineural Invasion

BCC has neurotropism - tendency for perineural spread
Potential for "skip lesions" secondary to neurotropism
Perineural invasion = HIGH RISK feature = Mohs surgery indicated

6. RISK STRATIFICATION (HIGH vs. LOW RISK BCC)

Low-Risk BCC

Nodular or superficial subtype only
No perineural invasion
Well-defined borders
Primary (not recurrent) disease
No prior radiation
< 10-mm diameter on M-area (cheek, forehead, scalp, or neck)

High-Risk BCC

Any size on H-area (central face, eyelids, nose, lips, chin, ears, temples, periauricular)
> 10-mm on M-area (cheek, forehead, scalp, neck)
Immunosuppression
Perineural invasion
Recurrent disease
Poorly defined borders
Aggressive histologic subtype (morpheaform, basosquamous, sclerosing, mixed infiltrative, micronodular)

FMGE Question Pattern: "3-mm auricular BCC" = HIGH RISK (H-zone). "8-mm BCC of the cheek" = LOW RISK (M-zone, < 10 mm). "12-mm BCC of forehead" = HIGH RISK (> 10 mm on M-area).

7. DIAGNOSIS AND WORKUP

Biopsy Types

Type	Indication
Shave biopsy	Nonpigmented superficial lesions
Narrow margin (1-3 mm) excisional	Concerning, but superficial-appearing lesions
Full-thickness punch / incisional	Large lesions not amenable to excision
Wide margin excision without biopsy	Discouraged (precludes sentinel node biopsy, further workup)
FNA	Concerning metastatic lymph nodes

Imaging

Contrasted CT or MRI (gadolinium if contrast allergy): assess cervical/parotid lymphadenopathy, bone involvement, perineural invasion, deep tissue extension
PET/CT: advanced metastatic disease, restaging

Histology Clue

Nodular BCC = palisading nuclei in peripheral cells
Basosquamous = keratinization + squamous differentiation

8. TREATMENT

Surgery (Gold Standard)

Situation	Margin
Low-risk BCC (< 2-cm, well circumscribed)	4-mm excision margin
High-risk BCC	Mohs micrographic surgery (preferred)
Scalp, hair-bearing areas	C&E not applicable; Mohs/excision

Mohs Micrographic Surgery:

Allows intraoperative assessment of 100% of excised margins
Gold standard for high-risk BCC
Lower recurrence vs traditional surgery (1-4% for primary BCC; 4-8% for recurrent BCC)
Particularly beneficial in H-zone (face, nose, eyelid, ear, periauricular)
For BCC: nodular type usually needs only 4-mm margins, but infiltrative/micronodular types need 5-10 mm for complete clearance
Mohs indications: recurrent BCC, sclerosing BCC, poorly differentiated tumors, need to preserve soft tissue (e.g., eyelid)

Curettage and Electrodesiccation (C&E):

For low-risk, non-hair-bearing area
Operator dependent

Radiation:

Primary option for nonsurgical candidates
Adjuvant: positive/unresectable margins, extensive perineural invasion, large nerve involvement
Contraindicated in Gorlin syndrome and other genetic predispositions to skin cancer, and in connective tissue disorders

Topical / Non-Surgical Options (Reserved for unfit for surgery/radiation)

Agent	Notes
5-Fluorouracil (5-FU)	Topical; superficial BCC
Imiquimod	Topical; immune modulator; superficial BCC
Photodynamic therapy (PDT)	Superficial BCC
Cryotherapy	Superficial BCC
Intralesional Interferon α-2B	Effective for low-risk superficial BCC; 3 injections/week × 3 weeks; side effects: flu-like symptoms; rarely used (expensive, challenging regimen)

Systemic Therapy

Hedgehog Pathway Inhibitors:

Vismodegib (Erivedge) - first approved
Sonidegib (Odomzo)
FDA approved for locally advanced recurrent BCC not amenable to surgery or radiation, and metastatic BCC
Mechanism: inhibit Smoothened (SMO) in the sonic hedgehog pathway (downstream of PTCH1)
Side effects: muscle spasms, dysgeusia (taste disturbance), alopecia, nausea, weight loss, fatigue, elevated creatine kinase

FMGE Fact: Vismodegib/Sonidegib = Hedgehog inhibitors = for advanced/metastatic BCC. Side effect to remember = dysgeusia + muscle cramps + alopecia.

9. NODAL METASTASIS FROM BCC

Very rare (< 0.1% of BCCs metastasize)
Treatment: therapeutic neck dissection + radiation
Consider hedgehog inhibitor or clinical trial
Sentinel lymph node biopsy (SLNB) is NOT standard of care for BCC (it IS standard for Merkel cell carcinoma)

FMGE Trick: SLNB = standard of care for Merkel cell carcinoma, NOT for BCC. BCC rarely metastasizes; SCC has 3-5% regional metastasis rate.

10. BCC vs SCC vs MCC - QUICK COMPARISON (FMGE High Yield)

Feature	BCC	SCC	MCC
Proportion of NMSC	70-75%	20%	5%
Most common site	Head/neck (nose)	Head/neck	Head/neck
Associated virus	None	HPV (some subtypes)	Polyomavirus (MCPyV)
AJCC staging	No formal staging	Yes	Yes
Metastatic potential	Very low (< 0.1%)	3-5% regional	High
SLNB standard of care	No	No (consider in high risk)	Yes
Histology	Palisading nuclei	Keratin pearls, intercellular bridges	Small blue cells, neuroendocrine
Most aggressive subtype	Morpheaform/Basosquamous	Poorly differentiated	N/A
Systemic therapy	Hedgehog inhibitors	EGFR inhibitors (cetuximab), cisplatin	Checkpoint inhibitors
Staging imaging	PET/CT for advanced	Contrasted CT	PET/CT most sensitive

FMGE Fact: MCC polyomavirus (MCPyV). PET/CT = most sensitive staging for MCC. Cetuximab = most common EGFR inhibitor for SCC. Gorlin syndrome = BCC (PTCH1 mutation).

11. GORLIN SYNDROME - DEEP DETAILS (FMGE Favorite)

Feature	Detail
Formal names	Nevoid BCC Syndrome / Gorlin Syndrome / Gorlin-Goltz syndrome
Gene	PTCH1 (chromosome 9q22-31)
Inheritance	Autosomal dominant
Pathway	Sonic hedgehog signaling (PTCH1 normally inhibits Smoothened)
BCCs	Multiple, early onset (< 35 years), often hundreds
Jaw	Odontogenic keratocysts (most pathognomonic finding)
Calcification	Falx cerebri calcification (early, bilateral, "railroad track" pattern)
Skeletal	Bifid/fused ribs, kyphoscoliosis, bridging of sella turcica
Neurological	Medulloblastoma (desmoplastic variant), meningioma, macrocephaly
Ophthalmic	Strabismus, cataracts, coloboma
Cardiac	Fibromas
Radiation	Absolutely contraindicated - induces hundreds of new BCCs

FMGE Mnemonic: "GORLIN" - Gene PTCH1, Odontogenic keratocysts, Ribs (bifid), Large head (macrocephaly), Inhibit radiation, Neuroendocrine tumors (medulloblastoma)

12. XERODERMA PIGMENTOSUM (XP) - BCC ASSOCIATION

Autosomal recessive
Defect in nucleotide excision repair (NER) of UV-damaged DNA
Photosensitive skin with multiple BCC epitheliomas
Also SCC and melanoma
Presents mainly in children
Management: strict sun avoidance

FMGE Contrast: XP = AR = NER defect = multiple BCCs + SCCs. Gorlin = AD = PTCH1 = multiple BCCs + jaw cysts.

13. BCC IN THE PAROTID REGION (ENT-Specific)

BCC of the face can metastasize by direct invasion to the parotid gland
Most parotid metastases from BCC involve by direct extension (unlike SCC which spreads via lymphatics)
Cutaneous SCC: about 5% metastasize to parotid or neck
Parotid bed lymph nodes are at-risk draining nodes for temple, cheek, and periauricular skin cancers

14. FOLLOW-UP AND PROGNOSIS

30-50% of patients develop recurrence within 5 years
Annual full body skin examination
Q6-12 months for first 2 years, then reduce frequency if no recurrence
Imaging as clinically indicated
Patient education: self-examination, sunscreen, avoid peak sun (10 AM - 2 PM)
5-year survival for NMSC overall: 90%

15. FMGE EXAM PRACTICE QUESTIONS (With Answers)

Q1. Which of the following BCCs is categorized as HIGH RISK?

A. Nodular BCC
B. 8-mm BCC of the cheek
C. 3-mm auricular BCC ✓
D. 12-mm BCC of the forehead

Explanation: Auricular BCC = H-zone = high risk regardless of size. 12-mm on forehead = M-zone but > 10 mm = also high risk. Trick: both C and D are high-risk, but 3-mm auricular BCC is the more classic "exam trap" as it shows that size alone doesn't determine risk - location matters.

Q2. The gene mutated in Gorlin syndrome encodes which receptor?

A. EGFR
B. VEGFR
C. Sonic hedgehog receptor (PTCH1) ✓
D. Smoothened

Explanation: PTCH1 encodes the patched receptor that normally inhibits Smoothened in the Sonic Hedgehog pathway. Mutation in PTCH1 leads to constitutive Smoothened activation.

Q3. Gold standard treatment for high-risk BCC of the nose is:

A. Wide local excision with 4-mm margins
B. Radiation therapy
C. Vismodegib
D. Mohs micrographic surgery ✓

Explanation: High-risk BCC (H-zone, aggressive subtype, perineural invasion) = Mohs surgery preferred. Mohs allows 100% margin assessment.

Q4. Which systemic drug is FDA approved for locally advanced, recurrent BCC not amenable to surgery?

A. Cetuximab
B. Cisplatin
C. Vismodegib ✓
D. Pembrolizumab

Explanation: Vismodegib (hedgehog inhibitor) is FDA approved for locally advanced/metastatic BCC. Cetuximab = EGFR inhibitor for SCC.

Q5. Which of the following about Merkel cell carcinoma is TRUE?

A. Associated with HPV
B. Accounts for 20% of NMSC
C. SLNB is NOT indicated
D. PET/CT is the most sensitive staging modality ✓

Explanation: MCC is associated with Merkel cell polyomavirus (MCPyV), not HPV. MCC = 5% of NMSC. SLNB IS standard of care for MCC. PET/CT = most sensitive for MCC staging.

Q6. Radiation is absolutely contraindicated in:

A. Xeroderma pigmentosum
B. Gorlin syndrome ✓
C. Both A and B ✓
D. Fanconi anemia

Explanation: Radiation is contraindicated in genetic conditions predisposing to cutaneous cancers - both XP and Gorlin syndrome, as well as connective tissue disorders.

Q7. Histological pattern of nodular BCC:

A. Keratin pearls
B. Intercellular bridges
C. Peripheral palisading nuclei ✓
D. Small blue cells (neuroendocrine)

Explanation: Nodular BCC = palisading nuclei at periphery of tumor nests. SCC = keratin pearls + intercellular bridges. MCC = small blue neuroendocrine cells.

Q8. "Rodent ulcer" refers to:

A. Squamous cell carcinoma
B. Merkel cell carcinoma
C. Ulcerated nodular BCC ✓
D. Morpheaform BCC

Explanation: "Rodent ulcer" is the classic description of an ulcerated nodular BCC. "Rodent ulcer" and "basal cell epithelioma" are antiquated synonyms for BCC.

Q9. Most common malignant tumor of the External Auditory Canal:

A. Basal cell carcinoma
B. Adenoid cystic carcinoma
C. Squamous cell carcinoma ✓
D. Melanoma

Explanation: EAC malignant tumors in order: SCC > BCC > Adenoid cystic carcinoma. BCC is second most common.

Q10. A BCC subtype characterized by "skip lesions" and high recurrence rate is:

A. Nodular
B. Superficial
C. Morpheaform/Sclerosing ✓
D. Basosquamous

Explanation: Morpheaform/sclerosing BCC has small tumor strands extending from central lesion = skip lesions due to neurotropism = high recurrence rates = Mohs surgery mandatory.

16. QUICK REVISION BULLET POINTS (Last-Minute FMGE Revision)

BCC = most common skin cancer / most common cancer in humans
BCC = 70-75% of NMSC; SCC = 20%; MCC = 5%
NO AJCC staging for BCC
Most common site: nose (head and neck overall most affected)
Key gene: PTCH1 (9q) = sonic hedgehog receptor = Gorlin syndrome
Gorlin syndrome = AD = BCC + odontogenic keratocysts + bifid ribs + falx calcification
Most common BCC = Nodular (pearly, telangiectasia, palisading nuclei)
Most aggressive BCC = Morpheaform (skip lesions, scar-like)
H-zone = high-risk area = nose, eyelid, ear, lip, temple, periauricular
Low-risk treatment: 4-mm excision
High-risk treatment: Mohs micrographic surgery
Mohs = 100% margin assessment = gold standard for H-zone, recurrent, morpheaform BCC
Radiation: contraindicated in Gorlin + XP + connective tissue disorders
Systemic therapy: Vismodegib / Sonidegib (hedgehog inhibitors) - for advanced/metastatic BCC
Hedgehog inhibitor side effects: dysgeusia, muscle spasms, alopecia, fatigue
Topical: 5-FU, imiquimod, PDT, cryotherapy (for superficial BCC)
Intralesional interferon α-2B: effective for low-risk superficial BCC; flu-like side effects
SLNB = standard for MCC (NOT BCC)
BCC metastasis = rare (< 0.1%); to parotid = by direct invasion
MCC virus = Polyomavirus (MCPyV); MCC = neuroendocrine tumor (CK20+)
Recurrence: 30-50% in 5 years; follow-up Q6-12 months × 2 years
XP = AR = NER defect; Gorlin = AD = PTCH1

Sources: KJ Lee's Essential Otolaryngology (9th ed.), Cummings Otolaryngology Head & Neck Surgery (7th ed.), Fitzpatrick's Dermatology (9th ed.), Andrews' Diseases of the Skin

This is a shared conversation. Sign in to Orris to start your own chat.